Clinical trials: Recurrent Bacterial Vaginosis (BV)
Bacterial Vaginosis
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in women with a history of recurrent BV.
- Trial name
- NCT02236156
- Testing
- Metronidazole oral tablets 500mg, 1% SPL7013 Gel
- Where
- 30 sites in United States, Bulgaria and 4 more
- Volunteers
- 637 people
- Sponsor
- Starpharma Pty Ltd
Bacterial Vaginosis (BV), Recurrent Bacterial Vaginosis
Evaluation of the Medical Device Vagitab - T as Adjuvant Therapy in Patients With Bacterial Vaginosis.
This clinical trial is looking at how well and safely the vaginal administration of Vagitab-T works . Vagitab-T is already on the market in several countries in Europe as a medical device.
- Trial name
- Vagitab (NCT06725888)
- Testing
- Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- S.I.I.T. Srl
Bacterial Vaginosis
Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients
This trial employed a multicenter, randomized, double-blind, parallel, placebo-controlled design to evaluate the preventive effect of BPR-101 capsules combined with metronidazole on the recurrence of BV, as well as the cure rate…
- Trial name
- NCT07483671
- Testing
- BPR-101 capsules:Investigational product for the treatment of BV
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chengdu Syncor Pharmaceutical Co., Ltd.
Recurrent Bacterial Vaginosis (BV)
Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)
The purpose in this clinical study is to determine the efficacy of SPL7013 Gel for the prevention of recurrence of bacterial vaginosis.
- Trial name
- NCT01437722
- Testing
- 1% SPL7013 Gel, 3% SPL7013 Gel
- Volunteers
- 205 people
- Sponsor
- Starpharma Pty Ltd
Vaginosis, Bacterial, Bacterial Vaginosis
Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis
The vagina is a dynamic muscular organ whose health relies on a Lactobacillus-dominant microbiota that maintains low pH and protects against infections.
- Conditions
- Vaginosis, Bacterial, Bacterial Vaginosis, Bacterial Vaginosis (BV)
- Trial name
- GYNBAL-RBV (NCT07527572)
- Testing
- Lactobacillus gasseri KABP®064 10e9 CFU/capsule
- Volunteers
- 160 people
- Sponsor
- Kaneka Americas Holding Inc.
Bacterial Vaginosis
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
A double-blind, phase 3 study to determine the efficacy of SPL7013 Gel when administered on alternate days for 16 weeks, compared to placebo gel in preventing the recurrence of BV in women with a history of recurrent BV.
- Trial name
- NCT02237950
- Testing
- Metronidazole oral tablets 500mg, 1% SPL7013 Gel
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 586 people
- Sponsor
- Starpharma Pty Ltd